Therapeutic Drug for Disease Accompanied by Disorders in Retinal Cells or Retinal Tissue
The present invention relates to a therapeutic drug for a disease accompanied by a disorder in retinal cells or a retinal tissue, the drug including a retinal tissue, the retinal tissue being of an allogeneic origin and having a three-dimensional structure, wherein an intended patient to be given the therapeutic drug is a patient affected by a disease accompanied by a disorder of retinal cells or a retinal tissue, to be given systemically, for 1 month or more after the administration of the therapeutic drug, no immunosuppressive agent aimed at preventing graft rejection.
1 . A therapeutic drug for a disease accompanied by a disorder in retinal cells or a retinal tissue, wherein the drug comprises a retinal tissue being of an allogeneic origin and having a three-dimensional structure,
wherein an intended patient to be given the therapeutic drug is a patient affected by a disease accompanied by a disorder of retinal cells or a retinal tissue, to be given systemically no immunosuppressive agent aimed at preventing graft rejection for 1 month or more after the administration of the therapeutic drug.
2 . The therapeutic drug according to claim 1 , wherein the intended patient is a patient to be given systemically no immunosuppressive agent aimed at preventing graft rejection before, during, and/or after the administration of the therapeutic drug.
3 . The therapeutic drug according to claim 1 , wherein the intended patient is a patient to be given locally no immunosuppressive agent aimed at preventing graft rejection, other than a steroidal anti-inflammatory drug and a calcineurin inhibitor before, during, and/or after the administration of the therapeutic drug.
4 . The therapeutic drug according to claim 1 , wherein the intended patient is a patient to be given locally one or more immunosuppressive agents selected from the group consisting of triamcinolone, fluocinolone, and a calcineurin inhibitor, aimed at preventing graft rejection before, during, and/or after the administration of the therapeutic drug,.
5 . The therapeutic drug according to claim 3 , wherein the intended patient is a patient to be given locally none of a steroidal anti-inflammatory drug and/or a calcineurin inhibitor, aimed at preventing graft rejection at least 1 month after the administration of the therapeutic drug.
6 . The therapeutic drug according to claim 1 , wherein the intended patient is a patient to be given no immunosuppressive agent aimed at preventing graft rejection before, during, and/or after the administration of the therapeutic drug.
7 . The therapeutic drug according to claim 1 , wherein the therapeutic drug comprises substantially no retinal pigment epithelial cells.
8 . The therapeutic drug according to claim 1 , wherein TGFβ is present at least on a surface of the retinal tissue.
9 . The therapeutic drug according to claim 1 , wherein a diameter in the major axis direction of the retinal tissue is 0.2 mm or more.
10 . The therapeutic drug according to claim 1 , wherein a total number of cells contained in a piece of the retinal tissue is 1×10 4 cells or more.
11 . The therapeutic drug according to claim 1 , wherein the surface of the retinal tissue has 50% or more by area of a continuous epithelial structure.
12 . The therapeutic drug according to claim 1 , wherein 50% or more of the total number of cells contained in a piece of the retinal tissue are cells expressing at least one of PAX6, Chx10, and Crx.
13 . The therapeutic drug according to claim 1 , wherein the retinal tissue is derived from a pluripotent stem cell.